



## 60-Month Efficacy of Ab-Interno Canaloplasty for the Treatment of Open-Angle Glaucoma

Poster

**Authors:** Mark J. Gallardo, MD; Brayden Koch, MS; Matthew S Porter, MD



**Purpose:** To report the 60-month outcomes of ab-interno canaloplasty performed with the iTrack microcatheter (Nova Eye Medical, Fremont, USA) as a standalone procedure or combined with cataract surgery.

**Method:** This single-center, retrospective case series included 81 eyes with primary open-angle glaucoma (POAG) who underwent canaloplasty w/o cataract surgery. Primary endpoints were intraocular pressure (IOP) and number of anti-glaucoma medications at 12, 24, 36, 48, 60 months.

**Results:** IOP (mmHg) and number of medications reduced from  $20.4 \pm 4.6$  and  $2.8 \pm 0.9$  preoperatively to  $13.2 \pm 1.9$  ( $p < 0.001$ ) and  $1.74 \pm 1.3$  ( $p = 0.007$ ) at 60 months ( $n = 27$ ). Eyes which received standalone canaloplasty ( $n = 10$  at 60-month) reduced IOP and medications from  $23.40 \pm 9.03$  and  $2.90 \pm 0.57$  at baseline to  $13.0 \pm 1.25$  ( $p = 0.006$ ) and  $2.00 \pm 1.76$  ( $p = 0.070$ ) at 60 months and those operated in combination with phacoemulsification ( $n = 17$ ) from  $19.88 \pm 3.95$  and  $2.24 \pm 1.35$  at baseline to  $13.3 \pm 2.23$  ( $p < 0.001$ ) and  $1.59 \pm 1.06$  ( $p = 0.055$ ) at 60 months.

**Conclusions:** Canaloplasty performed via an ab-interno surgical technique, with or without cataract surgery, was effective in reducing IOP up to 60 months.

**Disclosures:** Dr. Gallardo is a consultant to Nova Eye Medical. Dr Porter and Dr Koch have no financial disclosure